ArticleFrontiers in oncology2026
Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autologous hematopoietic stem-cell transplant(ASCT) following high-dose chemotherapy is an established treatment for selected pediatric solid tumors. However, data from low- and middle-income countries(LMICs) remain scarce, where outcomes may be influenced by limited supportive care infrastructure and higher infection risks. Most available reports focus primarily on neuroblastoma, with little evidence for other solid tumors. Methods: The study included children, adolescents, and young adults (CAYA,0-25 years) with solid tumors treated at a tertiary-care center in India, aiming to assess survival outcomes, engraftment kinetics, and toxicities. Data were collected from patient files and electronic databases for those who underwent ASCT between January 2008 and June 2025. Results: Out of 92 patients, median age was 6y (IQR,4-16) with 69.6% males. Diagnoses included: high-risk neuroblastoma(HRNB,52.2%), relapsed/refractory Ewing sarcoma(EWS,22.8%), relapsed/refractory germ-cell tumors(GCT,15.2%), retinoblastoma(RB,5.4%), and soft-tissue sarcoma (STS,4.4%). Forty-three (46.8%) underwent ASCT in relapse/refractory setting, while 49(53.2%) had upfront ASCT. Median CD34+cell dose was 5.7(IQR,3.5-6.9) million/kg, with a median cryopreservation duration of 16(IQR,8-49) days. Median time to neutrophil-engraftment was 11(IQR,9-12) days. The 3-year OS of the entire cohort was 50.6% (95%CI: 36.8-62.9), and EFS was 35.9% (95%CI: 23.6-48.3). Three-year OS for HRNB, relapsed/refractory-EWS, relapsed/refractory-GCT, STS and RB were 48.5%(95%CI: 29.2-65.3), 43.8% (95%CI: 17.8-67.4), 56.3%(95%CI: 20.9-80.9), 66.7% (95%CI: 5.4-94.5), and 50.0%(95%CI: 6.0-91.0), respectively. For HRNB and EWS, BuMel-140 had better OS than CEM-200 [HR = 0.15,95%CI:0.04-0.7,p=0.005]. Conclusion: ASCT yields acceptable outcomes for selected high-risk or relapsed/refractory pediatric solid tumors in LMICs, with outcomes in GCT comparable to global standards, based on experience from a high-volume transplant center.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.